Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations

A growing group of biotech startups looking to advance a lineup of potential stem cell cures for Type 1 diabetes can look to a big and very effective rival moving forward in the field.